Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Patients with active eating disorders or conditions where further weight changes would be harmful should be carefully evaluated by their provider before initiating this therapy
If you have questions about your specific insurance plan or want to learn more about our services, our specialists are here to help, at no cost to you
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
The Lists mobile-friendly digital edition will go live on 1 January 2026
J Lab Clin Med 70 , 158169 (1967)
